Researchers at University of Technology Sydney have developed nanoparticle-mediated targeting chimeras (NPTACs), a new technology that can degrade disease-causing proteins to treat conditions like dementia, brain cancer, and autoimmune disorders. The technology overcomes limitations of conventional targeted protein degradation tools and has shown strong preclinical results. The targeted protein degradation market is expected to exceed $10 billion USD by 2030.

Arvinas presented preclinical data showing enhanced antitumor activity when combining ARV-393 and glofitamab in a high-grade B-cell lymphoma model, with plans to initiate a Phase 1 clinical trial combination cohort in 2026.

Arvinas will present multiple research abstracts about vepdegestrant, an investigational drug for estrogen receptor positive breast cancer, at the San Antonio Breast Cancer Symposium in December 2025. The drug is being co-developed with Pfizer and is currently under FDA review.

Arvinas will present preclinical data for ARV-393, a PROTAC BCL6 degrader targeting non-Hodgkin lymphoma, at the 2025 ASH Annual Meeting in Orlando, Florida.

Arvinas presented promising preclinical data for ARV-806, a targeted protein degradation drug designed to address KRAS G12D mutations in cancers like pancreatic, colorectal, and lung cancer, demonstrating robust protein degradation and potential therapeutic benefits.

Arvinas will present preclinical data for ARV-806, a novel PROTAC degrader targeting mutant KRAS G12D, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Arvinas will present new clinical data for vepdegestrant, an investigational PROTAC estrogen receptor degrader, at the 2025 ESMO Congress, highlighting patient-reported outcomes and potential treatments for ER+/HER2- breast cancer.

Arvinas announced positive Phase 1 clinical trial results for ARV-102, an investigational drug targeting LRRK2 protein in Parkinson's disease. The drug demonstrated dose-dependent brain penetration, reduced protein levels, and showed promising biomarker changes in healthy volunteers and Parkinson's patients.

Arvinas will present clinical data for ARV-102, an investigational oral PROTAC degrader targeting LRRK2, at the 2025 International Congress of Parkinson's Disease and Movement Disorders in Honolulu.

Arvinas, a clinical-stage biotechnology company, will participate in two upcoming investor conferences: Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference, presenting its protein degradation therapies platform.

Arvinas presented preclinical data for its investigational PROTAC BCL6 degrader, ARV-393, showing significant single-agent activity in models of certain lymphoma subtypes and enhanced antitumor activity in combination with small molecule inhibitors in aggressive diffuse large B-cell lymphoma models.

Arvinas has submitted a New Drug Application to the FDA for vepdegestrant, a potential treatment for patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. The submission is based on positive results from the VERITAC-2 Phase 3 clinical trial.